Adaptimmune Therapeutics plc ADAPY
0.02 USD -0.01 (-28.00%)
At closeNov 10, 2026, 4:00 PM EST
0.0176 Day range 0.022
0.001 52-week range 0.07
- YTD
- -30.77%
- 1 year
- -40.00%
ADAPY revenue history
Revenue is income from the company’s ordinary business activities.
178,032,000 USD
FY 2024 · Period ended
Coverage: stale. Values in USD; not inflation adjusted.
Reporting currency is USD by the source’s USD conversion factor of 1; the source does not name the currency.
Scroll the table to see all values →
| Fiscal period | Period end | Revenue | YoY change | YoY % |
|---|---|---|---|---|
| FY 2024 | 2024-12-31 | 178,032,000 | 117,751,000 | 195.34% |
| FY 2023 | 2023-12-31 | 60,281,000 | 33,133,000 | 122.05% |
| FY 2022 | 2022-12-31 | 27,148,000 | 20,999,000 | 341.50% |
| FY 2021 | 2021-12-31 | 6,149,000 | 2,191,000 | 55.36% |
| FY 2020 | 2020-12-31 | 3,958,000 | 2,836,000 | 252.76% |
| FY 2019 | 2019-12-31 | 1,122,000 | -58,383,000 | -98.11% |
| FY 2018 | 2018-12-31 | 59,505,000 | 21,672,000 | 57.28% |
| FY 2017 | 2017-12-31 | 37,833,000 | 23,635,000 | 166.47% |
| FY 2016 | 2016-12-31 | 14,198,000 | Not available | Not available |
| FY 2015 | 2015-06-30 | 9,871,000 | 9,046,000 | 1096.48% |
| FY 2014 | 2014-06-30 | 825,000 | Not available | Not available |
Percentage growth is shown only when the same fiscal period one year earlier has a positive value. Missing periods are not estimated.
Company-reported financial statements. Retrieved 2025-10-31T11:55:19.000Z. Retrieval time is not a report date.
Open full statementsUse Add to watchlist above to save this stock.